JAMIE SCHWARTZ: Open Payments
NPI 1063015675 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$446 in 19 payments from 9 companies in 2025. Trend: 2023 $696 · 2024 $718 · 2025 $446
Food & beverage: $446
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 6 | $170 |
| MILLICENT US INC | 4 | $80 |
| Evofem Biosciences, Inc. | 2 | $45 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| Janssen Biotech, Inc. | 1 | $34 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $25 |
| Hologic Sales and Service, LLC | 1 | $22 |
| TOLMAR, INC. | 1 | $18 |
| Boston Scientific Corporation | 1 | $17 |
Products named: Veozah, Phexxi, FEMLYV, INTRAROSA, MYFEMBREE, ERLEADA, Lynkuet, NOVASURE.
Industry payments across NY — which companies pay providers there.
